HUP0000767A3 - Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders - Google Patents

Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Info

Publication number
HUP0000767A3
HUP0000767A3 HU0000767A HUP0000767A HUP0000767A3 HU P0000767 A3 HUP0000767 A3 HU P0000767A3 HU 0000767 A HU0000767 A HU 0000767A HU P0000767 A HUP0000767 A HU P0000767A HU P0000767 A3 HUP0000767 A3 HU P0000767A3
Authority
HU
Hungary
Prior art keywords
dimethoxynapht
tetrahydropyrid
trifluoromethylphenyl
cerebral
ethane
Prior art date
Application number
HU0000767A
Other languages
Hungarian (hu)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HUP0000767A2 publication Critical patent/HUP0000767A2/en
Publication of HUP0000767A3 publication Critical patent/HUP0000767A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HU0000767A 1997-02-03 1997-02-03 Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders HUP0000767A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (en) 1997-02-03 1997-02-03 Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Publications (2)

Publication Number Publication Date
HUP0000767A2 HUP0000767A2 (en) 2000-09-28
HUP0000767A3 true HUP0000767A3 (en) 2000-10-30

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000767A HUP0000767A3 (en) 1997-02-03 1997-02-03 Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders

Country Status (11)

Country Link
EP (1) EP0954311A1 (en)
JP (1) JP2001511141A (en)
AU (1) AU1607397A (en)
CA (1) CA2279326A1 (en)
CZ (1) CZ275399A3 (en)
EE (1) EE9900332A (en)
HU (1) HUP0000767A3 (en)
IL (1) IL130994A0 (en)
IS (1) IS5117A (en)
TR (1) TR199901722T2 (en)
WO (1) WO1998033502A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (en) * 1990-05-22 1994-11-10 Sanofi Sa USE OF 1- [2- (2-NAPHTYL) ETHYL] -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF BRAIN AND NEURAL DISORDERS.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (en) * 1990-05-23 1991-11-29 Midy Spa N-SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES PROCESS FOR THEIR PREPARATION, INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Also Published As

Publication number Publication date
CZ275399A3 (en) 1999-12-15
JP2001511141A (en) 2001-08-07
IS5117A (en) 1999-07-15
TR199901722T2 (en) 2000-08-21
CA2279326A1 (en) 1998-08-06
HUP0000767A2 (en) 2000-09-28
AU1607397A (en) 1998-08-25
EP0954311A1 (en) 1999-11-10
EE9900332A (en) 2000-02-15
WO1998033502A1 (en) 1998-08-06
IL130994A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
NO20004915L (en) Transdermal therapeutic system containing a D2 agonist and provided for the treatment of Parkinson's disease and a method for its preparation
IL136461A0 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0102656A3 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders and medicaments containing them
NO20001001D0 (en) Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue injuries
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL126589A (en) 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits
HUP9701193A3 (en) Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
HUP9802945A3 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
ZA988095B (en) New peptide mimetics for the treatment of bone metabolic disorders, methods for their production, and drugs containing these compounds.
HUP0000873A3 (en) The use of levobupivacaine in facial surgery
HUP0000767A3 (en) Use of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane for preparing medicines for the treatment of cerebral and neuronal disorders
HUP0104701A3 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders and medicaments containing the compounds
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
NO993728D0 (en) Use of 1- [4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyrid-1yl] -2- (6,7-dimethoxynaphth-2yl) ethane in the manufacture of medicaments for the treatment of cerebral and neuronal disorders
IL129647A0 (en) Substituted 4-(6-fluoro-(1H)-indol-3-YL)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
FR2800589B1 (en) ARTICULATED ARMCHAIR FOR MEDICAL USE, FOR THE DISABLED AND FOR RELAXATION
PL334942A1 (en) Application of 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1-il]-2-(6,7-dimethoxynapht-2-yl) ethane in production of drugs predestined to treat cerebral and neuronic diseases
GB2325229B (en) 2,3-Disubstituted cyclopentanone derivatives, process for producing the same, and medicinal use thereof
BR9714486A (en) Use of 1- [4- (3-trifluoromethylphenyl) - 1,2,3,6-tetrahydropyrid-1-yl] -2- (6,7-dimethoxynft-2-yl) ethane
AU3142793A (en) Transdermal delivery of (E)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-O- methyloxine HCL and related compounds in the treatment of cognitive disorders and for analgesia